Status:
UNKNOWN
Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI)
Lead Sponsor:
University of Zurich
Conditions:
Glioblastoma
Eligibility:
All Genders
20-70 years
Brief Summary
In the treatment of glioblastoma (GBM) neurosurgical resection of the tumor is usually considered a a first step of effective therapy. Radical resection of the tumor is highly beneficial to the patien...
Detailed Description
Precision of GBM-Resection Intraoperative marking of tumor tissue Combination of 5-ALA fluorescence and intraoperative MRI
Eligibility Criteria
Inclusion
- Inclusion criteria:
- patients with Glioblastoma multiforme (GBM)
- no other tumor types or metastases
- Exclusion criteria:
- Allergy against 5-ALA or Porphyrin
- Porphyria
- Pregnancy
Exclusion
Key Trial Info
Start Date :
August 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01208909
Start Date
August 1 2009
End Date
December 1 2011
Last Update
October 22 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UniversitätsSpital Zürich
Zurich, Switzerland